**Table S1. IFN- ELISpot response rates after three HIV-DNA immunizations.**

|  |  |  |  |
| --- | --- | --- | --- |
| Peptide pool | Immunization group (no, %a) | | |
|  | Group 1 | Group 2 | Group 3 |
| Gag I (p17) b | 1/7 (14%) | 1/7 (14%) | 3/8 (37%) |
| Gag II (p24) b | 1/7 (14%) | 2/7 (28%) | 1/8 (12%) |
| Gag CMDR | 1/6 (17%) | 2/7 (28%) | 1/7 (14%) |
| Env I (gp120 V1-V2) b | 1/7 (14%) | 0/7 | 0/8 |
| Env II (gp120 V3-V5) b | 0/7 | 0/7 | 0/8 |
| Env III (gp41) b | 0/7 | 0/7 | 0/8 |
| Env CMDR | 0/7 | 0/7 | 0/8 |
| Pol CMDR | 0/7 | 0/7 | 0/8 |
| Any Gag | 1/7 (14%) | 2/7 (28%) | 3/8 (37%) |
| Any Env | 1/7 (14%) | 0/7 | 0/8 |
| Gag or Env | 1/7 (14%) | 2/7 (28%) | 3/8 (37%) |

aFrequency of responders given as percentage of total number of evaluable vaccinees. bHIV-DNA-vaccine subtype A- and B-specific peptides. All peptides were 15-mers with 10-aa overlap. The protein specificity is indicated in parentheses. The peptides included in Gag CMDR, Env CMDR and Pol CMDR were specific for the HIV inserts in MVA and were 15-mers with 11-aa overlap.